Unlearn, a US company featured in Vintage Altaroc Odyssey 2021 has announced a strategic partnership with APST Research, a platform founded by Professor Thomas Meyer, a renowned expert in ALS research. This partnership will enable the integration of data from over 8,000 patients followed in APST's longitudinal study within Unlearn's digital twin technology.
These data include detailed information on disease progression, clinical assessments such as motor and respiratory function, and biomarker analyses including levels of light neurofilaments, indicators of neuronal deterioration. This partnership paves the way for faster, more targeted clinical trials.
A response to a growing challenge
Amyotrophic lateral sclerosis, which causes progressive degeneration of motor neurons, remains poorly understood and without a cure. With an expected 70% increase in the number of cases by 2040, there is an urgent need to accelerate research. The tools developed by Unlearn help to reduce the number of patients required for clinical trials, and to evaluate the efficacy of treatments more rapidly.
"Our digital twin technology is based on solid data," explains Steve Herne, CEO of Unlearn. "With APST, we gain access to one of the most comprehensive ALS databases, which will enable us to significantly reduce search times."
A step towards faster treatment
In addition to strengthening its database, Unlearn plans to collaborate with APST to publish work on the advances of digital twins in clinical trials. These virtual replicas accurately reproduce patient characteristics, enabling treatments to be evaluated under optimal conditions, while limiting constraints for participants.
"For the first time, APST is making its data available, offering a unique opportunity to accelerate clinical research," notes APST's Professor Thomas Meyer. "This collaboration marks a crucial step in our quest for a better understanding of ALS and new solutions for patients."
A platform that transforms clinical trials
With its technology, Unlearn optimizes all stages of trials: planning, execution and analysis. Its digital twins reduce the need for control groups, identify the most suitable patients for studies, and enable simulated scenarios to evaluate treatments more rapidly.
This partnership between Unlearn and APST, based on innovative technology and unique data, could mark a turning point in ALS research, offering new perspectives for researchers and, above all, for patients.
